Extracted from this filing and checked against the source text.
Debt Financings
SEC 8-K Item 2.03/2.04
confidence 0.95
Karyopharm Therapeutics Inc. incurred credit facility of $12.5 million with term loan lenders at not specified maturing not specified.
- Instrument
- credit facility
- Principal
- $12.5 million
- Counterparty
- term loan lenders
- Rate
- not specified
- Maturity
- not specified
- Event
- incurrence
Exact text from the filing
On the Closing Date and as disclosed in the Current Report on Form 8-K filed by the Company on October 8, 2025, the Company borrowed $12.5 million under its credit and guaranty agreement, as amended, by the First Amendment and Waiver to Credit and Guaranty Agreement dated as of October 7, 2025.
View on SEC.gov
Debt Financings
SEC 8-K Item 2.03/2.04
confidence 0.95
Karyopharm Therapeutics Inc. incurred convertible notes of $15.0 million aggregate principal amount of 9.00% senior secured convertible notes due 2028 and $103.5 million aggregate with holders of convertible notes and other investors at 9.00% maturing 2028 and 2029.
- Instrument
- convertible notes
- Principal
- $15.0 million aggregate principal amount of 9.00% senior secured convertible notes due 2028 and $103.5 million aggregate
- Counterparty
- holders of convertible notes and other investors
- Rate
- 9.00%
- Maturity
- 2028 and 2029
- Event
- incurrence
Exact text from the filing
On the Closing Date and as disclosed in the Current Report on Form 8-K filed by the Company on October 8, 2025, the Company issued $15.0 million aggregate principal amount of 9.00% senior secured convertible notes due 2028 and $103.5 million aggregate principal amount of 9.00% senior secured convertible notes due 2029.
View on SEC.gov